Licence extension application for use of nivolumab plus ipilimumab for first line treatment of Malignant Pleural Mesothelioma to be reviewed in the EU

The licence extension application was on based on results from pivotal Phase 3 CheckMate-743 trial, which met the primary endpoint of superior overall survival with nivolumab plus ipilimumab vs chemotherapy (pemetrexed and cisplatin or carboplatin).

Biospace Inc.